Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura.
Boctor
Fouad N
FN
Smith
John A
JA
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D007155:Immunologic Factors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use; D010951:Plasma Exchange / Q000379:methods*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000503:physiopathology / Q000628:therapy*; D000069283:Rituximab; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000069283:Rituximab; D014750:Vincristine; D008775:Methylprednisolone